The Biofluid Inflammometer™:

Advancing Physiologic Measurement Through Whole-Blood Rheology

​

Biofluid Technology, Inc. is developing an investigational point-of-care measurement platform designed to characterize the rheologic behavior of whole blood and explore its relationship to microvascular function, inflammation, and human disease.

Blood is not simply a carrier of biochemical markers. Its physical behavior—including viscosity and its response to changing shear conditions—can influence resistance to flow, tissue perfusion, and the microcirculatory environment. Yet these properties are not routinely characterized at the point of care.

​

The Biofluid Inflammometer™, built upon Biofluid Technology's Rapid Profile Viscometer (RPV) technology, is being developed to address this measurement gap. The platform is designed to rapidly characterize whole-blood rheology across a physiologically relevant range of shear conditions from a small-volume blood sample, creating a quantitative rheologic profile that can ultimately be evaluated alongside conventional clinical and laboratory information.

Our objective is to determine whether direct measurement of blood's physical behavior can provide useful physiologic information that complements traditional biochemical assessment and improves understanding of disease processes involving the microcirculation.

​

Technology Focus

​

Our development program is focused on an investigational measurement system designed to:

* Characterize whole-blood rheology across low, intermediate, and high shear conditions
* Generate quantitative rheologic profiles from small-volume blood samples
* Produce reproducible measurements suitable for scientific and translational investigation
* Integrate rheologic information with complementary clinical and laboratory data
* Support development of data-driven frameworks for investigating relationships among blood rheology, microvascular physiology, and disease

​

Current Development Program

​

Biofluid Technology has progressed from proof-of-concept development into systematic engineering verification and preclinical validation of the Biofluid Inflammometer™ platform.

​

Current work includes:

​

* Engineering refinement and characterization of the next-generation RPV platform
* Verification of the mathematical and analytical framework used to derive rheologic measurements
* Assessment of measurement precision, repeatability, and reproducibility
* Controlled testing using reference fluids and fresh human whole blood
* Characterization of whole-blood behavior across physiologically relevant shear conditions
* Development of standardized collection, measurement, and analytical workflows
* Preparation for subsequent translational and clinical investigation

​

This work is intended to establish the analytical performance and technical foundation necessary for rigorous evaluation of the platform in human studies.

​

Scientific Direction

​

Biofluid Technology's broader research program is exploring the hypothesis that the physical behavior of circulating blood contains physiologically meaningful information that is not fully represented by conventional biochemical biomarkers alone.

​

Changes in whole-blood rheology may reflect the combined influence of red blood cell properties, plasma composition, cellular interactions, hematocrit, and other factors affecting microvascular flow. By making these properties more readily measurable, the Biofluid Inflammometer™ is intended to provide a platform for investigating their relationships to inflammation, cardiovascular and microvascular dysfunction, and other systemic disease processes.

​

Our long-term goal is to help establish blood rheology as a practical, quantitative dimension of physiologic assessment and to determine where that information can meaningfully complement existing clinical measurements.

​

Development Pipeline

​

Our current development portfolio is centered on:

The Biofluid Inflammometer™ / Rapid Profile Viscometer (RPV) — an investigational platform for rapid characterization of whole-blood rheology across physiologically relevant shear conditions.

​

Biofluid Technology is also evaluating complementary measurement and analytical approaches that may expand the physiologic information obtainable from blood and support future generations of the platform.

​

Important Notice

​

The Biofluid Inflammometer™, Rapid Profile Viscometer (RPV), and other technologies under development by Biofluid Technology, Inc. are investigational. They have not been cleared or approved by the U.S. Food and Drug Administration and are not currently intended for diagnostic or clinical use.